{"title":"Management of pemphigus during COVID-19 pandemic era: An experience of single centre.","authors":"Sahibzada Mahmood Noor, Farah Sagheer, Adan Sardar","doi":"10.47391/JPMA.10935","DOIUrl":null,"url":null,"abstract":"<p><p>The management of pemphigus vulgaris disease was challenging during the coronavirus diseases-2019 pandemic. The current study was planned to determine whether or not rituximab increases the risk and severity of coronavirus diseases-2019 infection in pemphigus vulgaris patients. The retrospective study was conducted at the Lady Reading Hospital, Peshawar, Pakistan, and comprised data from the dermatology unit of 34 diagnosed cases of pemphigus vulgaris who received rituximab treatment from March 2020 to March 2022. The mean age of the patients was 36.58±12.44 years. Majority of patients 28(82.3%) received rituximab as a second-line therapy, while 6(17.64%) were given it as a first-line therapy. Only 1(2.9%) patient developed mild covid pneumonia, and did not need in-patient care or faced oxygen dependence. There was a significant weak association between coronavirus diseases-2019 positivity with age (p=0.000). Rituximab therapy could be given to pemphigus patients during the pandemic, but only when necessary.</p>","PeriodicalId":54369,"journal":{"name":"Journal of the Pakistan Medical Association","volume":"75 3","pages":"469-471"},"PeriodicalIF":0.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pakistan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47391/JPMA.10935","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
The management of pemphigus vulgaris disease was challenging during the coronavirus diseases-2019 pandemic. The current study was planned to determine whether or not rituximab increases the risk and severity of coronavirus diseases-2019 infection in pemphigus vulgaris patients. The retrospective study was conducted at the Lady Reading Hospital, Peshawar, Pakistan, and comprised data from the dermatology unit of 34 diagnosed cases of pemphigus vulgaris who received rituximab treatment from March 2020 to March 2022. The mean age of the patients was 36.58±12.44 years. Majority of patients 28(82.3%) received rituximab as a second-line therapy, while 6(17.64%) were given it as a first-line therapy. Only 1(2.9%) patient developed mild covid pneumonia, and did not need in-patient care or faced oxygen dependence. There was a significant weak association between coronavirus diseases-2019 positivity with age (p=0.000). Rituximab therapy could be given to pemphigus patients during the pandemic, but only when necessary.
期刊介绍：
Primarily being a medical journal, JPMA publishes scholarly research focusing on the various fields in the areas of health and medical education. It publishes original research describing recent advances in health particularly clinical studies, clinical trials, assessments of pathogens of diagnostic importance, medical genetics and epidemiological studies. Review articles highlighting importance of various issues in the domain of public health, drug research and medical education are also accepted. As a leading journal of South Asia, JPMA remains cognizant of the recent advances in the rapidly growing fields of biomedical sciences, it invites and encourages scholars to write short reviews and invited editorials on the emerging issues. We particularly aim to promote health standards of developing countries by encouraging manuscript submissions on issues affecting the public health and health delivery services.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
